Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Structure Therapeutics

Structure Therapeutics (NASDAQ: GPCR) insider transactions

In the twelve months to 10 November 2026, executives and directors of Structure Therapeutics reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Structure Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
21 September 2026Coll Crespo BlasChief Medical OfficerConversion, 10b5-1 plan−12,024—258,228Form 4
18 September 2026Coll Crespo BlasChief Medical OfficerShares withheld for tax, 10b5-1 plan−10,626$11.67270,252Form 4
1 September 2026Lin XichenChief Scientific OfficerOption exercise, 10b5-1 plan+17,817$0.34246,777Form 4
1 September 2026Lin XichenChief Scientific OfficerConversion, 10b5-1 plan−17,817—228,960Form 4
18 August 2026Lin XichenChief Scientific OfficerOption exercise, 10b5-1 plan+11,817$0.34240,777Form 4
18 August 2026Lin XichenChief Scientific OfficerConversion, 10b5-1 plan−11,817—228,960Form 4
6 August 2026Berrios John JosephChief Commercial OfficerGrant or award+140,766—140,766Form 4
4 August 2026Lin XichenChief Scientific OfficerOption exercise, 10b5-1 plan+11,817$0.34240,777Form 4
4 August 2026Lin XichenChief Scientific OfficerConversion, 10b5-1 plan−11,817—228,960Form 4
14 July 2026Lin XichenChief Scientific OfficerOption exercise, 10b5-1 plan+23,634$0.34252,594Form 4
14 July 2026Lin XichenChief Scientific OfficerConversion, 10b5-1 plan−23,634—228,960Form 4
25 June 2026Lin XichenChief Scientific OfficerOption exercise, 10b5-1 plan+23,634$0.34252,594Form 4
25 June 2026Lin XichenChief Scientific OfficerConversion, 10b5-1 plan−23,634—228,960Form 4
15 April 2026Lang MatthewCOO & GCGrant or award+184,614—184,614Form 4
19 March 2026Stevens Raymond CChief Executive OfficerGrant or award+260,217—1,401,593Form 4
19 March 2026Hall AshleyChief Development OfficerGrant or award+47,706—155,187Form 4
19 March 2026Yoon JunChief Financial OfficerGrant or award+104,085—1,401,656Form 4
19 March 2026Lin XichenChief Scientific OfficerGrant or award+43,368—228,960Form 4
19 March 2026Ma YingliChief Technology OfficerGrant or award+32,526—139,917Form 4
19 March 2026Coll Crespo BlasChief Medical OfficerGrant or award+75,897—280,878Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Structure Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.